The rationale and design of the beta-blocker to LOwer CArdiovascular Dialysis Events (BLOCADE) feasibility study

Roberts, Matthew A., Pilmore, Helen L., Ierino, Francesco L., Badve, Sunil V., Cass, Alan, Garg, Amit X., Hawley, Carmel M., Isbel, Nicole M., Krum, Henry, Pascoe, Elaine M., Tonkin, Andrew M., Vergara, Liza A., Perkovic, Vlado and The BLOCADE Study Collaborative Group (2015) The rationale and design of the beta-blocker to LOwer CArdiovascular Dialysis Events (BLOCADE) feasibility study. Nephrology, 20 3: 140-147. doi:10.1111/nep.12362


Author Roberts, Matthew A.
Pilmore, Helen L.
Ierino, Francesco L.
Badve, Sunil V.
Cass, Alan
Garg, Amit X.
Hawley, Carmel M.
Isbel, Nicole M.
Krum, Henry
Pascoe, Elaine M.
Tonkin, Andrew M.
Vergara, Liza A.
Perkovic, Vlado
The BLOCADE Study Collaborative Group
Title The rationale and design of the beta-blocker to LOwer CArdiovascular Dialysis Events (BLOCADE) feasibility study
Journal name Nephrology   Check publisher's open access policy
ISSN 1440-1797
1320-5358
Publication date 2015-03
Sub-type Article (original research)
DOI 10.1111/nep.12362
Volume 20
Issue 3
Start page 140
End page 147
Total pages 8
Place of publication Richmond, VIC Australia
Publisher Wiley-Blackwell
Collection year 2016
Language eng
Formatted abstract
Aims:    The Beta-blocker to LOwer CArdiovascular Dialysis Events (BLOCADE) Feasibility Study aims to determine the feasibility of a large-scale randomized controlled trial with clinical endpoints comparing the beta-blocking agent carvedilol with placebo in patients receiving dialysis.
Methods:    The BLOCADE Feasibility Study is a randomized, double-blind, placebo-controlled, parallel group feasibility study comparing the beta-blocking agent carvedilol with placebo. Patients receiving dialysis for ≥3 months and who are aged ≥50 years, or who are ≥18 years and have diabetes or cardiovascular disease, were eligible. The primary outcome was the proportion of participants who complete a 6-week run-in phase in which all participants received carvedilol titrated from 3.125 mg twice daily to 6.25 mg twice daily. Other measures included how many patients are screened, the proportion recruited, the overall recruitment rate, the proportion of participants who remain on study drug for 12 months and the incidence of intra-dialytic hypotension while on randomized treatment.
Results:    The BLOCADE Feasibility Study commenced recruiting in May 2011 and involves 11 sites in Australia and New Zealand.
Conclusions:    The BLOCADE Feasibility Study will inform the design of a larger clinical endpoint study to determine whether beta-blocking agents provide benefit to patients receiving dialysis, and define whether such a study is feasible.
Keyword Beta-blocking agent
Feasibility study
Haemodialysis
Peritoneal dialysis
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Official 2016 Collection
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 1 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 2 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 10 Mar 2015, 00:40:06 EST by System User on behalf of Scholarly Communication and Digitisation Service